In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price target of $27.00. The company’s shares closed last Monday at $19.00.
According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -21.4% and a 25.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Hancock Jaffe Laboratories, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $33.20 average price target, an 89.7% upside from current levels. In a report released yesterday, Mizuho Securities also assigned a Buy rating to the stock with a $43.00 price target.
The company has a one-year high of $23.91 and a one-year low of $8.32. Currently, Coherus Biosciences has an average volume of 1.07M.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CHRS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar.